VolitionRx Limited announced that its Nu.Q® NETs H3.1 assay will be the sole biomarker used in the DETECSEPS real‑world evaluation of early sepsis across France. The program, funded with €6.3 million (about $7.3 million) under the France 2030 health innovation plan, will deploy the assay in nine hospital networks in five countries, beginning with partners in Paris and Lyon.
The partnership places VolitionRx’s CE‑marked Nu.Q® NETs test at the center of a national effort to improve sepsis detection and reduce mortality. The assay delivers a rapid, one‑hour result on the IDS i10 automated analyzer supplied by Euroimmun, and is expected to enhance the existing NEWS2 clinical score, supporting earlier intervention in emergency departments.
This collaboration marks a strategic expansion into the European human‑diagnostics market, where the company has previously focused on veterinary products. By securing a role in a government‑funded program, VolitionRx opens a large public‑health customer base and creates a pathway for future licensing and distribution agreements, potentially generating recurring revenue and milestone payments as the program progresses.
Management highlighted the significance of the partnership: Chief Medical Officer Dr. Andrew Retter noted that the assay’s rapid turnaround could save lives, while Professor Djillali Annane, scientific director of DETECSEPS, emphasized that combining the biomarker with NEWS2 could markedly improve early sepsis identification. Professor Sébastien Beaune, coordinating investigator, underscored the program’s potential to reduce the socio‑economic burden of sepsis.
The DETECSEPS program is led by IHU SEPSIS, part of the France 2030 plan’s €7.5 billion health innovation budget. The program’s national scope and government backing provide a robust validation platform for VolitionRx’s technology and signal strong confidence in its clinical utility.
Overall, the partnership represents a pivotal milestone for VolitionRx, positioning the company for broader adoption of its Nu.Q platform in human diagnostics and setting the stage for future commercial expansion across Europe.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.